ScopeSys Inc.

Market position

ScopeSys positions its CLiC platform against existing analytical technologies that rely on ensemble measurements, offering single-molecule and single-particle resolution for genomic-medicine development. It is tracked as a Canadian corporate research institution in the Nature Index, where it is credited with one primary research article (Share 0.24) in the 1 May 2025 - 30 April 2026 window, ranked 6,946 globally and 177 in Canada overall, and 1,136 globally and 39 in Canada among corporate institutions, with output classified under health sciences and the topic of medical biotechnology.

Technology

The company's technology is Convex Lens-induced Confinement (CLiC), a single-molecule imaging approach that confines molecules for optical measurement and enables high-throughput data collection at single-molecule resolution. Unlike ensemble measurement techniques, CLiC is described as resolving individual molecular interactions, allowing analysis of active pharmaceutical ingredients and formulations such as mRNA lipid nanoparticles, including mRNA loading at single-particle resolution and nanoparticle behaviour under changing environmental conditions.

Go-to-market

ScopeSys presents itself as a commercial-stage company that engages industry and leading drug developers through collaborations, positioning its platform to address customer-specific analytical questions.

Developers of genomic medicines, including organizations working on RNA and DNA therapeutics and nanoparticle-delivered drugs, as well as industry partners engaged in formulation and sequence optimization.

Geography

The company is based in Canada and originated from the University of British Columbia; Nature Index records domestic research collaboration with the University of British Columbia (78.2% of collaboration Share) and international collaboration with the University of Gothenburg (21.8%).